Mice study offers insight into how the brain balances risk and reward

Every day, our brain makes thousands of decisions, big and small. Any of these decisions – from the least consequential such as picking a restaurant to the more important such as pursuing a different career or moving to a new city – may result in better or worse outcomes.

Boehringer seeks approval for lung fibrosis drug following Phase III win

Boehringer’s nerandomilast is a preferential inhibitor of phosphodiesterase 4B (PDE4B). Image credit: Tada Images / Shutterstock. Boehringer Ingelheim is seeking regulatory approval for nerandomilast after

September 16, 2024

Study unveils a potential solution to combat age-related immune system decline

As we age, our bodies face numerous challenges, including a decline in immune system function and an increased vulnerability to various health issues.

September 7, 2023

Organigram Sells Units to Raise C$25 MIllion

Organigram Announces Pricing of Overnight Marketed Public Offering TORONTO–(BUSINESS WIRE), March 27, 2024–Organigram Holdings Inc. (“Organigram” or the “Company”) (TSX: OGI; NASDAQ: OGI), announces today

March 27, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.